ISSN:
1435-1463
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Bromocriptine and the two ergoline derivatives, CQ 32-084 and CM 29-712, excert dopamine-like effects in experimental models and have been shown to possess antiparkinsonian activity. Biochemical investigations indicate that they differ in their specificity towards the different dopamine receptor types and, in addition, interact with other neurotransmitter receptors. Bromocriptine appears to be a potent agonist at D2-receptors. Furthermore, it blocks adenylate cyclase coupled serotonin receptors and antagonizes centralα-adrenergic receptors. The two ergoline derivatives are multiple agonists. CQ 32-084 stimulates both D1- and D2-, and CM 29-712 only D2-receptors. In addition, both compounds stimulate adenylate cyclase coupled serotonin receptors and antagonize centralα-adrenergic receptors.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01664004
